- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05498974
China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
The aim of the China Diabetes Type 1 Study (CD1S) is to conduct a nationwide type 1 diabetes (T1D) registry study in patients with T1D and in pediatric adolescent patients with diabetes who had an age of onset <= 20 years.
CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Zhiguang Zhou, MD, PhD
- Phone Number: +8673185292154
- Email: zhouzhiguang@csu.edu.cn
Study Contact Backup
- Name: Xia Li, MD, PhD
- Email: lixia@csu.edu.cn
Study Locations
-
-
Gansu
-
Lanzhou, Gansu, China
- Recruiting
- Gansu Provincial People's Hospital
-
-
Guangdong
-
Shenzhen, Guangdong, China
- Recruiting
- Shenzhen Second People's Hospital
-
Contact:
- Dewen Yan
-
-
Hainan
-
Haikou, Hainan, China, 570311
- Recruiting
- Hainan General Hospital
-
-
Heilongjiang
-
Harbin, Heilongjiang, China
- Recruiting
- The First Affiliated Hospital of Harbin Medical University
-
Contact:
- Hongyu Kuang
-
-
Henan
-
Luoyang, Henan, China
- Recruiting
- The First Affiliated Hospital of Henan University of Science and Technology
-
Contact:
- Hongwei Jiang
-
-
Hunan
-
Changsha, Hunan, China, 410000
- Recruiting
- The Second Xiangya Hospital, Central South University
-
Contact:
- Xia Li, MD, PhD
- Email: lixia@csu.edu.cn
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Not yet recruiting
- The First Affiliated Hospital of Nanjing Medical University
-
Contact:
- Tao Yang
-
-
Shanxi
-
Changzhi, Shanxi, China
- Recruiting
- Heji Hospital Affiliated to Changzhi Medical College
-
Contact:
- Xiaohong Niu
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830017
- Recruiting
- The first affiliated hospital of Xinjiang medical university
-
Contact:
- Sheng Jiang
-
-
Yunnan
-
Kunming, Yunnan, China
- Recruiting
- The First People's Hospital of Yunnan
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Zhejiang Provincial People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
1. Patients with type 1 diabetes mellitus of any duration; meeting criteria (1) or any of (2) or any of (3)
- Clinical diagnosis of type 1 diabetes by a specialist
- Age at onset < 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide < 200 pmol/L
- Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset <= 20 years, regardless of type and duration of disease.
Exclusion Criteria:
For enrolment of patients with T1D, exclusion was made if any of the following criteria were met (not applicable to those with onset under 20 years of age)
No insulin dependence for at least 6 months after diagnosis of diabetes mellitus.
- No DKA for 1 month off insulin for those with a history of diabetes > 1 year. ③ C-peptide > 800 pmol/L at any time point.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Individuals diagnosed with type 1 diabetes
All patients diagnosed with type 1 diabetes of all ages.
|
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
|
Individuals with diabetes who had an age of onset <= 20 years.
All patients with diabetes who had an age of onset <= 20 years.
|
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in serum hemoglobin A1c level
Time Frame: Every year for up to 10 years
|
A1c reflects the average blood glucose level
|
Every year for up to 10 years
|
Albumin-to-creatinine ratio in urine sample
Time Frame: up to 10 years
|
Albumin-to-creatinine ratio in urine sample
|
up to 10 years
|
Arteriosclerotic cardiovascular diseases
Time Frame: up to 10 years
|
Incident cases of cardiovascular diseases
|
up to 10 years
|
Electromyography
Time Frame: up to 10 years
|
value of nerve conduction velocity, F wave index, H-reflex
|
up to 10 years
|
PHQ-9
Time Frame: up to 10 years
|
PHQ-9(a score between 0-27, ≥10 may indicate depression)
|
up to 10 years
|
GAD-7
Time Frame: up to 10 years
|
GAD-7(a score between 0-21, ≥5 may indicate general anxiety)
|
up to 10 years
|
WHO-5
Time Frame: up to 10 years
|
WHO-5 (a score between 0-100, higher score means better outcome)
|
up to 10 years
|
PAID
Time Frame: up to 10 years
|
PAID (a score between 0-100, ≥40 warrants special attention).
|
up to 10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in C-peptide
Time Frame: Every year for up to 10 years
|
C-peptide are measured before and 2-hour after a mixed meal tolerance test at each follow-up of this study
|
Every year for up to 10 years
|
Change in titer of autoantibodies
Time Frame: Every year for up to 10 years
|
Glutamic acid decarboxylase antibody
|
Every year for up to 10 years
|
Fasting blood glucose
Time Frame: Every year for up to 10 years
|
the blood sugar level after fasting for eight hours
|
Every year for up to 10 years
|
Systolic blood pressure
Time Frame: Every year for up to 10 years
|
Systolic blood pressure
|
Every year for up to 10 years
|
Diastolic blood pressure
Time Frame: Every year for up to 10 years
|
Diastolic blood pressure
|
Every year for up to 10 years
|
Change in lipid profiles
Time Frame: Every year for up to 10 years
|
Including triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol
|
Every year for up to 10 years
|
Metabolomics
Time Frame: Every year for up to 10 years
|
un-targeted metabolomics
|
Every year for up to 10 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zhiguang Zhou, MD, PhD, The Second Xiangya Hospital, Central South University
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD1S
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Göteborg UniversityKarolinska University Hospital; The Swedish Research Council; Swedish Council... and other collaboratorsRecruiting
-
HaEmek Medical Center, IsraelCompleted